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with stable/ refractory disease fared similarly with regard to OS
and PFS. Day 100, 2-year TRM and OS/PFS data appear very
encouraging in these very high-risk, extensively pretreated pa-
tients. Response status at transplant seems to affect outcome, and
PD remains a major obstacle.
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VACCINATION WITH DENDRITIC CELL MYELOMA FUSIONS ALONE OR
IN CONJUNCTION WITH STEM CELL TRANSPLANTATION FOR PATIENTS
WITH MULTIPLE MYELOMA
Avigan, D.1, Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Bisonette, A.2,
Macnamarra, C.1, Uhl, L.1, Lenahan, C.1, Miller, K.1, Joyce, R.1,
Levine, J.1, Proper, J.1, Forino, P.1, Donbagoda, D.1, Munshi, N.2,
Kufe, D.2 1Beth Israel Deaconess Medical Center, Boston, MA; 2Dana
Farber Cancer Institute, Boston, MA.
We have demonstrated that patient derived myeloma cells fused
with autologous dendritic cells (DCs) potently stimulate anti-tu-
mor immunity in vitro. We are conducting phase I clinical trials in
which patients with myeloma undergo serial vaccination with DC/
myeloma fusions alone or in conjunction with stem cell transplan-
tation. To date, 18 patients have been enrolled (11- vaccine alone,
7 vaccine following autologous stem cell transplant). To generate
mature DCs, adherent mononuclear cells were isolated from a
leukapharesis collection and cultured with GM-CSF, IL-4, and
TNF . The mean yield and viability of the DC preparations was
1.5  108 cells and 88%, respectively. Patient derived myeloma
cells were isolated from bone marrow aspirates and were quantiﬁed
by the expression of CD38 and/or CD138. The mean yield and
viability of the myeloma cell collections was 7.3  107 cells and
89%, respectively. Fusion cells were generated by coculture of
DCs with myeloma cells in the presence of 50% polyethylene
glycol. The mean fusion efﬁciency was 40% as determined by the
percentage of cells that co-expressed unique DC and myeloma
antigens. In contrast to myeloma cells, the DC and fusion cell
preparations prominently stimulated allogeneic T cell proliferation
in vitro. To date, 13 patients have completed vaccination at a dose
of 1-5  106 fusion cells. GM-CSF (100 g) was administered
subcutaneously on the day of vaccination and for 3 days thereafter.
Adverse events judged to be potentially vaccine related have in-
cluded vaccine injection site reactions, edema, rash, fever, chills,
fatigue, muscle aches, pruritis, and diarrhea. One patient with a
history of prior deep venous thrombosis (DVT) developed a DVT
and pulmonary embolus of uncertain relation to the vaccine. To
date, a majority of evaluable patients demonstrated evidence of
vaccine induced anti-myeloma immunity as demonstrated by at
least 2 fold increase in IFN expression by CD4 and/or CD8 T
cells in response to ex vivo exposure to autologous tumor lysate. Of
patients undergoing vaccine therapy alone, 5 patients demon-
strated stabilization of the myeloma paraprotein for 2-6 months
following initiation of vaccination. Of 3 patients completing post-
transplant vaccination, 2 patients demonstrated resolution of the
persisting myeloma protein post-transplant and 1 patient demon-
strated a transient increase followed by a decline in paraprotein
levels post-transplant.
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INTERLEUKIN-6 AND HEMATOPOIETIC SOLUBLE FACTORS CONFERS
RESISTANCE TO TRAIL MEDIATED APOPTOSIS
Perez, L.E.1, Parquet, N.1, Shain, K.2, Molisano, M.1,
Nimmanapalli, R.2, Alsina, M.1, Anasetti, C.1, Dalton, W.2 1BMT
Division, H. Lee Mofﬁtt Cancer Center, Tampa, FL; 2Hematology
Division, H. Lee Mofﬁt Cancer Center, Tampa, FL.
The bone marrow microenvironment provides tumor protection
from chemotherapy and Fas-death receptor mediated apoptosis
through a process known as environmental mediated death resis-
tance (EM-DR). TRAIL, a member of the TNF superfamily, has
anti-tumor activity sparing normal cells and mediates allogeneic
graft-versus-tumor responses. We hypothesized that the tumor
microenvironment inﬂuences TRAIL mediated killing conferring
an immune resistance mechanism contributing to cancer progres-
sion in allogeneic transplantation. Experiments in a transwell
(TW) assay with RPMI-8226-Myeloma cells in the upper well and
HS5- hematopoietic stromal cells in the bottom well (TWHS5)
revealed that HS5 cells blocked recombinant human(rh-) TRAIL-
induced apoptosis through soluble factors in a dose and time-
dependent manner. RPMI-8226 treated in TWHS5 exhibited
attenuated pro-caspase-8, pro-caspase-3, PARP, and BID cleavage,
with diminished mitochondrial membrane potential changes, with-
out alterations on TRAIL receptors. Western blotting of RPMI-
8226 cells showed that Fas-associated death domain like IL-1
converting enzyme-like inhibitory protein (FLIP), a regulatory
factor that competes with caspase-8 inhibiting apoptosis, is in-
creased in TWHS5 treated cells. Subcellular fractionation of
RPMI-8226 cells showed that FLIP is maintained in or associated
with organelle membranes and is released to the cytosol when
exposed to soluble factor (TWHS5) suggesting that that soluble
factor signaling may inﬂuence FLIP localization and availability.
FLIP reduction by FLIP-RNA interference or with Bortezomib,
NF-KB inhibitor that reduces FLIP levels, increases TRAIL apo-
ptosis sensitivity of RPMI-8226 cells treated in TWHS5. To
explore whether IL-6, important myeloma survival factor, is in-
volved in TRAIL-EMDR, RPMI-8226 treated with HS27a stroma
that lack IL-6 secretion elicit a diminished apoptosis resistance
compared to HS-5. In addition, RPMI-8226 treated in TWHS5
with an anti-human IL-6 neutralizing antibody partially overcome
the TRAIL apoptosis resistance. Furthermore, rh-IL-6 confers
resistance to TRAIL mediated apoptosis in a dose-dependent man-
ner associated with FLIP increase. Our results suggest that IL-6
and other soluble factors produced by marrow stromal cells pro-
mote myeloma cell survival by upregulating FLIP, thereby miti-
gating the inﬂuence of the microenvironment on TRAIL-induced
apoptosis. The immune cytotoxic effect of TRAIL may be en-
hanced by FLIP inhibitors.
PEDIATRIC DISORDERS
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THE USE OF CYCLOPHOSPHAMIDE (CY), FLUDARABINE AND ATG AS A
PREPARATIVE REGIMEN FOR UNRELATED CORD BLOOD TRANSPLAN-
TATION (UCBT) IN FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE
IN 27 PATIENTS
Bonﬁm, C.1, Bitencourt, M.1, Setubal, D.1, Funke, V.1, Ruiz, J.1,
Oliveira, M.1, Coutinho, E.1, deMedeiros, C.1, Zanis-Neto, J.1,
Pasquini, R.1 1Stem Cell Transplantation Unit UFPR, Curitiba,
Parana, Brazil.
Stem cell transplantation from HLA identical siblings can cure
over 80% of FA pts when they develop bone marrow failure
syndromes. Unrelated CB is a good option for pts lacking a
matched bone marrow unrelated donor, but the transplant pro-
cedure is complicated by a high incidence of graft failure and
delayed immune recovery. From 01/03 to 05/06 we transplanted
27pts with FA in aplastic phase. Gender: 8M/19F. Age:4-
19years (M:8y). Disease duration: 19-78months (M:36m). Pre-
vious transfusions : 1-85UI (M:12) .HLA Compatibility: 6/6:
3pts ; 5/6:9pts and 4/6:15pts. Preparatory regimen: CY60mg/
kg Fludarabine125mg/m2  Rabbit ATG 4mg/kg. GVHD
Prophylaxis: Cyclosporine (Csa)  steroids:22pts or Csa 
MTX: 5pts.TNC infused before thawing: 2,3 – 19,2 10^7/kg
(M: 5,4). One pt received a double UCBT with a TNC of 5,2
10^7. Results: 11pts are alive between 135-1301 days after
UCBT(M: 806d). 21pts survived  28 d and were evaluable for
engraftment. 13pts (48%) had a complete hematological recov-
ery and the median time to reach ANC500/ul was 23 d(12-
35d) and platelets  20.000/ul was 27 d(15-50d). Primary graft
failure occurred in 6pts and 2pts had only a neutrophil engraft-
ment. Most pts (6/8pts) without hematological recovery re-
ceived a 4/6 CB. No pt survived a 2nd or 3rd UCBT. Post-
transplant complications: Mucositis grade III-IV: 10pts (grade
IV: 1pt). Hemorrhagic cystitis: 5pts.Hemolytic uremic syn-
drome:1pt. Moderate/severe hypertension: 70% of pts. Neuro-
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logical toxicity: 8pts (cycloporine toxicity /CNS bleeding/ neu-
rotoxoplasmosis). Acute GVHD: grade III-IV: 4/15pts and
C-GVHD extensive: 5/11pts. Six pts had EBV reactivation and
4pts developed disease associated symptoms(2pts: high grade
NHL). 16 pts died between 7-120 days after UCBT(M: 47d).
Causes of death were mainly related to severe bacterial and
fungal infections. TRM: 44%. Overall survival for pts with good
HLA compatibility(5/6 or 6/6) was 56% compared to 28% after
a 4/6 UCBT (p:0.22). Conclusions: CYFLUATG im-
proved the survival of pts receiving a 5/6 or 6/6 UCBT. In
developing countries most pts have been exposed to CMV,EBV
or toxoplasmosis and close monitoring of viral reactivation as
well as aggressive treatment of bacterial infections are necessary
in order to decrease TRM. In this group,4/6 UCBT was asso-
ciated with a high incidence of rejection and TRM but the
survival did not reach statistical signiﬁcance probably due to the
small number of pts.
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION IN PEDIATRIC PATIENTS WITH HEMATOLOGIC MALIG-
NANCIES FOLLOWING SINGLE-DOSE TOTAL BODY IRRADIATION
Druley, T.E.1, Hayashi, R.J.1, Barnes, Y.J.1, Jean, Z.4, David, M.2,
Kathryn, T.4, Shannon, W.1, Tia, T.1, Eric, K.2, John, D.F.3,
Douglas, A.A.3, Shalini, S.1 1Washington University School of Medi-
cine, Division of Pediatric Hematology and Oncology, Saint Louis, MO;
2Department of Radiation Oncology, Saint Louis, MO; 3Division of
Medical Oncology, Bone Marrow Transplantation and Leukemia Sec-
tion, Saint Louis, MO; 4Department of Biostatistics, Saint Louis, MO.
Background: Fractionated total body irradiation (TBI) as condi-
tioning in allogeneic hematopoietic cell transplants (HCT) for
hematologic malignancies results in successful donor cell engraft-
ment and disease-free survival. However, standard TBI is associ-
ated with early organ toxicities and late impairment of growth,
development and endocrine function, especially in children. We
have previously shown that modiﬁed single-dose (SD) TBI condi-
tioning was well tolerated and successful in achieving engraftment
in adults.
Method: To decrease radiation-induced toxicity, SD TBI was
adopted for conditioning in pediatric hematologic malignancies. A
low total dose (550 cGy) was delivered at a high dose rate (30
cGy/min) after cyclophosphamide (60 mg/kg x2) followed by stem
cell infusion. GVHD prophylaxis included cyclosporine and short
course methotrexate. Methylprednisolone was included for URD
HCT.
Results: Since 1998, 57 children were transplanted using this
regimen. Recipient demographics are described in Table 1. Over
half were either in second remission or beyond, and had high risk
disease. Bone marrow was the stem cell source in 72%; 63% were
URD HCT. Median follow-up was 14 months (range 1-68).
Transplant outcomes are described in Table 1.
All patients, even when heavily pre-treated, tolerated the condi-
tioning well. Acute toxicities included grade 3-4 mucositis (21%),
invasive infections (11%), veno-occlusive disease (4%), renal fail-
ure (4%), multiorgan failure/shock (12%) and hemolytic anemia
(7%). The 100-day TRM was low (12%). The non-relapse mor-
tality after day 100 was 6%. Graft rejection and acute and chronic
GVHD rates were low (Table); GVHD-induced mortality was 7%.
There was no graft rejection after day 100. OS and DFS at one year
were 59% and 46%, thus comparable with standard TBI-based
conditioning. Immune reconstitution (determined by T and B cell
numbers and function) returned to normal range at one year post
HCT in the absence of GVHD.
Conclusions: SD TBI was well tolerated and supported donor
cell engraftment with low rates of GR, TRM and GVHD, even in
children with heavily pre-treated disease. Early OS and DFS were
comparable to standard TBI-based conditioning. This approach is
hence worthy of a larger trial in children with longer follow up to
compare late toxicities and DFS.
Table 1: Recipient Demographics and Outcome
Total patients 57
Median age (years) 11.3 (1.0-20.5)
Male/Female 40 (70%)/17 (30%)
Acute lymphoblastic leukemia 34 (60%)
Acute myelogenous leukemia 17 (30%)
Non-Hodgkin’s lymphoma 6 (10%)
CR1/ CR2/ CR3 37%/53%/9%
Refractory disease 1 (2%)
Bone marrow/ Peripheral blood 41 (72%)/16 (28%)
Matched sibling donor 21 (37%)
6/6 antigen/allele matched
unrelated donor (URD) 24 (42%)
5/6 matched URD 12 (21%)
Follow up (months) 14 (1-68)
ANC>500/dl: platelets>20,000/dl
(days) 13 (9-22): 18 (7-49)
Day 100 donor chimerism:
full/mixed/none 78%/ 11%/ 11%
Treatment-related mortality (TRM)
(day 100) 12%
Grade 2-4 aGVHD/ cGVHD
26% (CI 15-37%)/
40% (CI 28-52%)
Overall survival (OS) (1 year) 59% (CI 44-70%)
Disease-free survival (DFS) (1 year) 46% (CI 32-58%)
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CHEST RADIOGRAPH VERSUS COMPUTED TOMOGRAPHY IN THE DI-
AGNOSIS OF ACUTE PULMONARY COMPLICATIONS IN PEDIATRIC
STEM CELL TRANSPLANT
Duncan, C.N.1, Buonanno, M.P.1, Cormier, C.1, Lehmann, L.E.1
1Dana-Farber Cancer Institute, Boston, MA.
Pulmonary complications cause signiﬁcant morbidity in the acute
stem cell transplant (SCT) period. Early identiﬁcation of a pulmo-
nary process can lead to earlier intervention and potentially im-
proved survival. The choice of a pulmonary imaging modality
should provide accurate and useful diagnostic information in a
timely manner. A chest radiograph (CXR) is frequently used when
investigating a pulmonary process as it can be rapidly obtained in
the transplant room without the need for sedation. Chest com-
puted tomography (CT) scans have greater accuracy than a CXR.
However, a chest CT scan may not be able to be immediately
obtained, may require sedation and cannot be done in the trans-
plant room. We investigated the diagnostic utility of chest CT
scans compared with CXR during the initial SCT admission. We
performed a retrospective review of all pediatric SCT performed at
our institution between January 1, 2004 and September 1, 2006. Of
the 194 patients transplanted 34 (17.5%) had a total of 60 chest
CTs during the initial transplant admission. Indications for chest
CT were pulmonary symptoms without fever (33.3%), follow-up
of previous radiographic study (15%), neutropenic fever (13.3%),
non-neutropenic fever (11.7%), non-neutropenic fever with pul-
monary symptom (11.7%), neutropenic fever with pulmonary
symptom (8.3%), chest pain (5%), and abdominal pain (1.7%). 49
patients also had a CXR performed within 72 hours of their CT. 36
scans were performed within 72 hours of a normal CXR. 22
(61.1%) of these provided new diagnostic information, including:
new airspace disease or opacity (19 scans), new pleural effusion or
signiﬁcant difference in size of effusion (4 scans), new pericardial
effusion (3 scans), and a new epipericardial mass (1 scan). Of the
CT scans with a new diagnosis following a normal CXR, 81.8%
were made in patients with pulmonary symptoms. 14 (38.9%) of
the CTs done within 72 hours of normal CXR were normal. 13 CT
scans were done within 72 hours of an abnormal CXR. 12 of these
had an abnormal CT scan which provided more detail, but no new
diagnoses. The remaining CT was within normal limits in the
setting of an abnormal CXR. CXR and chest CT are useful diag-
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